WithdrawnPhase 1/2

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Stopped: Sponsor decision

United States0Started 2020-12-15

Plain-language summary

The study is a designed to evaluate safety and activity of APG-1252 when administered as monotherapy and in combination with ruxolitinib in previously ruxolitinib treated myelofibrosis patients.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Either primary or post essential thrombocythemia/polycythemia vera
. Have intermediate-2 or high-risk myelofibrosis by International Prognostic Scoring System (IPSS) scoring system
. If intermediate-1 myelofibrosis must have palpable splenomegaly ≥ 5 cm below left costal margin
. Either in chronic (CP) or accelerated phase (AP)
. Patients can be either JAK2 wild type or JAK2V617F mutated
. Absolute neutrophil count (ANC) ≥ 0.750 X 10˄9/L
. Hemoglobin (Hb) ≥ 9.0 g/dL
. Platelets count ≥ 50 X 10˄9/L (independent of transfusion within14 days of first dose)

Exclusion criteria

. Unstable arrhythmia on treatment including permanent cardiac pacemaker
. History of symptomatic congestive heart failure (New York Heart Association \[NYHA\] Class III or IV)
. History of myocardial infarction within 6 months of enrollment

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Dose-limiting toxicity (DLT) rate at each dose level

Timeframe: 28 days

Spleen Volume Measurement Reduction

Timeframe: 24 weeks

Trial details

NCT IDNCT04354727

SponsorAscentage Pharma Group Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-12-15

View on ClinicalTrials.gov More Myelofibrosis trials